| | |

Predicting Unresectable Mesothelioma Prior to Surgery

ByAlex Strauss
unresectable mesothelioma

Cancer researchers at Baylor have found an effective way to identify certain cases of unresectable mesothelioma without making an incision.

They focused on a common reason a surgeon might decide not to operate, even after the patient is on the table. The condition, called DCWI, is hard to identify without opening the patient up. 

But the Baylor team says there is a non-invasive way to identify DCWI and predict cases of unresectable mesothelioma. If it works, it could save patients the pain of surgery. It could also save lives by allowing doctors to start other mesothelioma treatments sooner. 

Diffuse Chest Wall Invasion in Mesothelioma

Diffuse chest wall invasion (DCWI) is a condition that can make it impossible to perform effective mesothelioma surgery.

DCWI means the mesothelioma tumor has spread to or “invaded” the wall of the chest. When mesothelioma is widespread on the chest wall, it is “diffuse”. DCWI is not easy to spot with imaging studies. Surgeons usually discover DCWI when they open the chest to do mesothelioma surgery.

Too much cancer on the chest wall results in unresectable mesothelioma. Surgeons have to close the patient back up and choose a different type of therapy. Unfortunately, by the time this happens, the patient may have lost valuable treatment time. 

Predicting Unresectable Mesothelioma by Finding DCWI

The Baylor researchers wanted to find out if there were preoperative variables associated with DCWI. If there were variables, they wanted to see if they could be measured.  

The group conducted a retrospective study using the medical records of 170 pleural mesothelioma patients. Patients were slated for mesothelioma surgery at Baylor between 2014 and 2018. 

One-hundred-and-four patients had lung sparing PD surgery. Thirty-nine patients underwent EPP surgery. The remaining 27 patients who went under the knife were found to have unresectable mesothelioma. In 24 patients, this was because of DCWI. The other three patients had cancer in some of their organs. 

The researchers found that the amount of space inside the patients’ rib cage – also called thoracic cage volume – was linked to DCWI. Thoracic cage volume can be measured with a CT scan.

“In univariable analysis, decreased ipsilateral thoracic cage volume demonstrated the strongest association with unresectability by DCWI,” writes study author Bryan Burt, MD. 

Dr. Burt says patients with more than a  5% decrease in thoracic cage volume were most likely to be inoperable.

Applying the Findings in Mesothelioma Management

Dr. Burt and his colleagues say watching for a decrease in thoracic cage volume may be a safer, easier way to predict unresectability. There are many potential advantages to finding unresectable mesothelioma without having to operate. 

“Preoperative identification of DCWI will avoid unnecessary thoracotomy [chest wall incision] and accelerate initiation of nonsurgical therapy in malignant pleural mesothelioma,” they write. 

The team is calling for further studies to validate the finding. 

Source:

Burt, B, et al, “Preoperative prediction of unresectability in malignant pleural mesothelioma”, November 27, 2019, Journal of Thoracic and Cardiovascular Surgery, Epub ahead of print, https://www.jtcvs.org/article/S0022-5223(19)33489-0/abstract

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…